TickerFacts.

Company research / BMRN

BioMarin Pharmaceutical Inc (BMRN)

Build a valuation ↗↓ Download CSV

SEC name BIOMARIN PHARMACEUTICAL INC · CIK 0001048477 · Nasdaq · Pharmaceutical Preparations

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, BioMarin Pharmaceutical Inc reported revenue of $3.22B. Revenue grew 12.9% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $3.41B.

Key ratios (year ended 2025-12-31)

77.7%
Gross margin (computed)
12.7%
Operating margin
10.8%
Net margin
5.7%
Return on year-end equity
12.9%
Revenue growth (YoY)

Computed by TickerFacts from revenue minus cost of revenue. This may differ from the issuer's reported gross profit or margin; check the revenue and cost definitions.

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 8-K (current report) · 2026-10-06

Headquarters locality: Novato · View on map

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-06-30		2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$3.41B$3.22B$2.85B$2.42B$2.10B$1.85B$1.86B$1.70B$1.49B$1.31B$1.12B
Cost of Revenue$813.59M$717.44M$580.24M$532.06M$503.02M$470.51M$524.27M$359.47M$315.26M$241.79M$209.62M
Gross Profit (computed)$2.59B$2.50B$2.27B$1.89B$1.59B$1.38B$1.34B$1.34B$1.18B$1.07B$907.23M
R&D Expense$987.64M$921.93M$747.18M$746.77M$649.61M$628.79M$628.12M$715.01M$696.33M$610.75M$661.90M
Operating Income$149.26M$409.48M$484.21M$185.77M$160.97M-$82.34M-$43.44M-$100.46M-$123.52M-$14.70M-$803.43M
Depreciation & Amortization$152.97M$79.56M$96.43M$104.39M$101.97M$108.04M$105.17M$105.30M$95.67M$87.86M$96.91M
EBITDA$302.23M$489.04M$580.64M$290.16M$262.94M$25.70M$61.73M$4.84M-$27.85M$73.16M-$706.52M
Net Income$72.97M$348.90M$426.86M$167.65M$141.56M-$64.08M$854.03M-$23.85M-$77.21M-$117.04M-$630.21M
EPS (Diluted)n/a$1.80$2.21$0.87$0.75-$0.35$4.50-$0.13-$0.44-$0.67-$3.81
Total Assets$11.72B$7.59B$6.99B$6.84B$6.38B$6.00B$5.85B$4.69B$4.43B$4.63B$4.02B
Total Liabilities$5.40B$1.51B$1.33B$1.89B$1.77B$1.74B$1.74B$1.57B$1.46B$1.82B$1.26B
Shareholders' Equity$6.32B$6.09B$5.66B$4.95B$4.60B$4.27B$4.10B$3.12B$2.97B$2.81B$2.77B
Cash & Equivalents$874.00M$1.31B$942.84M$755.13M$724.53M$587.28M$649.16M$437.45M$493.98M$598.03M$408.33M
Operating Cash Flow$857.09M$827.99M$572.84M$159.26M$175.90M$304.54M$85.36M$48.26M$20.21M-$8.76M-$227.84M
Capital Expenditures$118.91M$103.04M$85.42M$96.69M$120.96M$95.58M$114.31M$145.03M$144.62M$199.22M$148.38M
Free Cash Flow$738.18M$724.96M$487.42M$62.57M$54.94M$208.96M-$28.95M-$96.76M-$124.41M-$207.98M-$376.22M
Share Repurchasesn/an/an/an/a$0$0$50.00M$0$0n/an/a
Shares Outstanding193.54M192.30M190.76M188.60M186.25M183.91M181.74M179.84M178.25M175.84M172.65M
Weighted Average Diluted Sharesn/a197.39M196.71M191.59M188.96M182.85M191.68M179.04M177.27M174.43M166.22M
EPS (Basic)n/a$1.82$2.25$0.89$0.76-$0.35$4.72-$0.13-$0.44-$0.67-$3.80

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView